Tesamorelin

Overview

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), a signaling molecule that prompts the pituitary gland to release growth hormone. It is most commonly discussed in the context of reducing visceral adipose tissue — the deep abdominal fat that surrounds internal organs.

Unlike many peptides in the research space, tesamorelin is FDA-approved. It was cleared in 2010 under the brand name Egrifta to reduce excess abdominal fat in people with HIV-associated lipodystrophy, a condition in which fat is redistributed to the trunk, often in connection with antiretroviral therapy.

Because its approval is specific to that HIV-related indication, any other use — such as general body composition or anti-aging goals — is off-label and not something regulators have evaluated for those purposes.

How it works

Tesamorelin binds to GHRH receptors in the pituitary gland and stimulates the release of the body’s own growth hormone, which in turn raises circulating IGF-1. Because it works upstream of growth hormone rather than replacing it directly, this approach is intended to preserve the natural pulsatile pattern and feedback controls of the growth-hormone axis.

The molecule is a modified form of GHRH designed to resist enzymatic breakdown, which is thought to give it more sustained signaling than unmodified GHRH. The downstream rise in growth hormone and IGF-1 is the mechanism most often linked to its observed effect on visceral fat.

Reported benefits

• Reduction of visceral abdominal fat in HIV-associated lipodystrophy (its approved, clinically studied use)
• Studied for reductions in liver fat in HIV-associated fatty liver disease (emerging evidence)
• Associated improvements in certain lipid measures such as triglycerides in clinical trials

These reflect findings largely from HIV-specific study populations and are not guaranteed outcomes in other groups.

Considerations & side effects

Because tesamorelin raises growth hormone and IGF-1, commonly reported side effects include joint pain, fluid retention or swelling, muscle aches, and injection-site reactions. Effects on blood sugar and glucose tolerance have been examined, and clinicians generally monitor these during use. Its benefit on visceral fat has been reported to reverse after the medication is stopped.

Most of the strong clinical evidence comes from studies in people with HIV, so how well those findings generalize to other populations is less established. It is not a substitute for evaluation and treatment by a qualified clinician, who can weigh individual risks such as diabetes or a history of cancer.